Respiratory Disease

Respiratory·MeSH: Respiration Disorders

Prevalence

7379.3 / 100K

Incidence

1082.5 / 100K/yr

7 drugs in development·7 companies·1 clinical trial

Drug Pipeline by Phase

Phase 2(1)

Drug	Company
ATI-052	Aclaris Therapeutics, Inc. (ACRS)

Phase 1(4)

Drug	Company
aio-001	Syneos Health, Inc. (SYNH)
alvr106	Kalaris Therapeutics, Inc. (KLRS)
DVX201 (Unmodified Natural Killer Cells)	Coeptis Therapeutics Holdings Inc. (COEP)
tp-271	TETRAPHASE PHARMACEUTICALS INC (TTPH)

Preclinical(2)

Drug	Company
man-19	Q BioMed Inc. (QBIO)
tp-271	LA JOLLA PHARMACEUTICAL CO (LJPC)

BioSniper tracks 7 drugs in development for Respiratory Disease across 7 companies.

There are 1 clinical trial targeting Respiratory Disease tracked by BioSniper.

The estimated prevalence of Respiratory Disease is approximately 7379.3 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.